DA-PROTAC

Cat. No.:	HY-147373
CAS No.:	2488660-12-2
Molecular Formula:	$C_{46}H_{50}BrF_2N_7O_8S_2$
Molecular Weight:	1010.96
Target:	PROTACs; Ligands for E3 Ligase
Pathway:	PROTAC
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DA-PROTAC is a potent PROTAC degrader of copper ion-transport proteins Atox1 and CCS. DA-PROTAC can bind both Atox1 and CCS proteins, and the complex can be bound to E3 ligase, leading to increased levels of ubiquitination of Atox1 and CCS and degradation of Atox1 and CCS proteins via the proteasome pathway. DA-PROTAC can be used for triple negative breast cancer research[1].
IC_{50} & Target	VHL
In Vitro	DA-PROTAC (0-1 μM, 24 h) can degrade Atox1 and CCS proteins rather than inhibit Atox1 and CCS activity[1]. DA-PROTAC (5 μM, 24 h) inhibits the proliferation, migration and invasion of triple negative breast cancer cells (MDA-MB-231)[1]. DA-PROTAC (10 μM, 48 h) inhibits the tumorigenic capacity of triple negative breast cancer cells (MDA-MB-231)[1]. The targeting module of DA-PROTAC is a small molecule VHL ligand1 combined with E3 ligase[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	MDA-MB-231 cells
Concentration:	100 nM ,200 nM ,500 nM , and 1000 nM
Incubation Time:	24 h
Result:	Significantly reduced ATOX1 and CCS protein levels under 200nM, indicating that DA-PROTAC can degrade ATOX1 and CCS proteins.

REFERENCES

[1]. Zhao Yicheng, et al. Small-molecule inhibitor for degrading copper ion transporter Atox1 and CCS and application thereof. CN111471054A.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA